Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1528 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Rapid and Sustained Pain Relief in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels and Correlated with Improvement in Fatigue
Atul A. Deodhar¹, Philip G. Conaghan², Tore K Kvien³, Vibeke Strand⁴, Lawrence Rasouliyan⁵, Brian Porter⁶, Steffen Jugl⁷ and Kunal Gandhi⁶, ¹Oregon Health & Science University, Portland, OR, ²University of Leeds, Leeds, United Kingdom, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Stanford University School of Medicine, Palo Alto, CA, ⁵RTI Health Solutions, Barcelona, Spain, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab has demonstrated sustained efficacy in patients (pts) with active AS.1,2 We investigated improvement in pain and fatigue scores from baseline (BL) through Week…
Abstract Number: 1565 • 2017 ACR/ARHP Annual Meeting
Depression and Fatigue in Patients with Ankylosing Spondylitis
Ji Hui Shin¹, Sun Ju Ahn² and Tae-Hwan Kim³, ¹rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Medical Research Coordinator, Hanyang Univerity Hospital for Rheumatic Disease Research Center, Seoul, Korea, Republic of (South), ³Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that leads to bony ankyloses. The disease occurs in early adulthood, a critical stage in life,…
Abstract Number: 2524 • 2017 ACR/ARHP Annual Meeting
Weight Change before and after Diagnosis in Patients with Psoriatic Arthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis
Alexis Ogdie¹, Michael D. George², Joel Gelfand³, Maureen Dubreuil⁴, Thorvardur Love⁵ and Joshua Baker⁶, ¹Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania Health System , Philadelphia, PA, ⁴Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ⁵Landspitali University Hospital, Reykjavik, Iceland, ⁶Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rheumatoid arthritis (RA) has been associated with weight loss around the time of diagnosis; little is known about weight change around diagnosis in…
Abstract Number: 614 • 2017 ACR/ARHP Annual Meeting
Effect of Tofacitinib on Reducing Pain in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Alexis Ogdie¹, Kurt de Vlam², Iain B. McInnes³, Philip J Mease⁴, Philip Baer⁵, Tatjana Lukic⁶, Kenneth Kwok⁶, Cunshan Wang⁷, Ming-Ann Hsu⁷ and Anna Maniccia⁶, ¹Division of Rheumatology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UZ Leuven, Leuven, Belgium, ³Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Baer Weinberg MPC, Scarborough, ON, Canada, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), which has also been evaluated in other inflammatory rheumatic diseases…
Abstract Number: 1529 • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Consistent Safety over Long-Term Exposure (up to 3 years) in Patients with Active Ankylosing Spondylitis: Pooled Analysis of Three Phase 3 Trials
Atul A. Deodhar¹, Xenofon Baraliakos², Helena Marzo-Ortega³, Joachim Sieper⁴, Mats Andersson⁵, Brian Porter⁶ and Todd Fox⁵, ¹Oregon Health & Science University, Portland, OR, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³NIHR LBRC, LTHT and LIRMM, UoL, Leeds, United Kingdom, ⁴Charité University Medicine Berlin, Berlin, Germany, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab has demonstrated a consistent and reliable safety profile in three Phase 3 studies in ankylosing spondylitis (AS): MEASURE 1 (NCT01358175), MEASURE 2 (NCT01649375),…
Abstract Number: 1570 • 2017 ACR/ARHP Annual Meeting
Monocytes from Male Patients with Ankylosing Spondylitis Display Decreased Osteoclastogenesis and Decreased RANKL/OPG Ratio
Valéria F. Caparbo¹, Carla G.S. Saad¹, Julio C. B. Moraes², Artur J de Brum-Fernandes³ and Rosa M R Pereira⁴, ¹Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Brazil, ³Rheumatology Division, Université de Sherbrooke, Rheumatology Division, Canada, Sherbrooke, QC, Canada, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disease characterized by new bone growth that leads to syndesmophyte formation and subsequent vertebral ankyloses, although AS…
Abstract Number: 2537 • 2017 ACR/ARHP Annual Meeting
Changes in Severity, Functional Status, and Wellbeing over Time Among Individuals with Ankylosing Spondylitis (AS) in Canada: Results from the RHUMADATA® Multicentre Registry
Shelagh Szabo¹, Sara Chehab², Louis Coupal³ and Denis Choquette⁴, ¹Broadstreet HEOR, Vancouver, BC, Canada, ²Novartis Pharmaceuticals Canada Inc., Montreal, QC, Canada, ³Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁴University of Montreal Hospital Research Centre (CRCHUM), Notre Dame Hospital Montreal, Montreal, QC, Canada
Background/Purpose: While changes in disease severity, functional status, and patient wellbeing are commonly measured in AS trials, longitudinal data from real-world cohorts are fewer; particularly…
Abstract Number: 629 • 2017 ACR/ARHP Annual Meeting
Is Earlier Golimumab Treatment Initiation in Psa and As Patients Associated with Improved Outcomes?
Suneil Kapur¹, Proton Rahman², Michelle Teo³, Jodie Reis⁴, Rajwinder Dhillon⁵, Pauline Boulos⁶, Raman Rai⁷, Regan Arendse⁸, Julie Vaillancourt⁹, Emmanouil Rampakakis⁹, Allen J Lehman¹⁰, Francois Nantel¹¹ and Brendan Osborne¹¹, ¹University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ²Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ³Balfour Medical Clinic, Penticton, BC, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Private Practice, Niagara Falls, ON, Canada, ⁶Private Practice, Dundas, ON, Canada, ⁷Private Practice, Hamilton, ON, Canada, ⁸University of Saskatchewan, Saskatoon, ON, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have suggested that treating patients earlier with biologics could improve disease outcomes. The aim of this analysis was to assess the impact…
Abstract Number: 1530 • 2017 ACR/ARHP Annual Meeting
Improvements in Sleep Problems and Pain in Patients with Active Ankylosing Spondylitis Treated with Intravenous Golimumab: 28-Week Results of the Phase III Trial
Atul A. Deodhar¹, John D. Reveille², Eric K. H. Chan³, Steven Peterson⁴, Nan Li⁴, Elizabeth C. Hsia⁵, Lilianne Kim⁴, Kim Hung Lo⁴, Diane D. Harrison⁴ and Chenglong Han⁶, ¹Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ²University of Texas McGovern Medical School, Houston, TX, ³Janssen Global Services, LLC, Raritan, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁶Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To investigate the effect of intravenously administered (IV) golimumab (GLM, 2 mg/kg), an anti-TNFα monoclonal antibody, on sleep problems, total back pain (TBP), and…
Abstract Number: 1572 • 2017 ACR/ARHP Annual Meeting
MHC Associations of Ankylosing Spondylitis in East Asians Are Driven By HLA-B Amino-Acid Position 97, Confirming Findings in European Descent Subjects
Geng Wang¹, Adrian Cortes², So-Young Bang³, Paul Leo⁴, Matthew Brown⁴, Tae-Hwan Kim⁵ and Huji Xu¹, ¹Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China, ²Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁴Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, ⁵Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: Whilst HLA-B27 is the MHC allele associated with AS, there is strong evidence indicating that other HLA-B alleles and MHC genes are involved in…
Abstract Number: 2748 • 2017 ACR/ARHP Annual Meeting
Immunogenicity of Infliximab Among Patients with Behcet’s Syndrome: A Controlled Study
Sinem Nihal Esatoglu¹, Fatma Nihan Akkoc¹, Yesim Ozguler¹, Fatma Ozbakir², Okan Kadir Nohut², Dilsen Cevirgen³, Vedat Hamuryudan¹, Ibrahim Hatemi⁴, Aykut Ferhat Celik⁵, Hasan Yazici¹ and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Central Research Laboratory, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of and Rheumatology, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Immunogenicity of anti-TNFs has been recognized as an important problem that may cause loss of response and adverse events such as infusion reactions. We…
Abstract Number: 661 • 2017 ACR/ARHP Annual Meeting
Normal Human Enthesis Contains a Resident Population of γδT-Cells
Richard Cuthbert¹, Evangelos M. Fragkakis¹, Robert Dunsmuir², Peter Giannoudis³, Elena Jones¹, Darren Newton⁴ and Dennis McGonagle¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Department of Spinal Surgery, National Health Service, Leeds, United Kingdom, ³Academic Department of Trauma and Orthopaedics, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom
Background/Purpose: Recent animal studies have suggested that γδT-cells accumulate at enthesis, secrete IL-17 and are responsible for driving the spondyloarthritis (SpA) phenotype resulting from IL-23…
Abstract Number: 1531 • 2017 ACR/ARHP Annual Meeting
Effects of Intravenous Golimumab on Patient-Reported Outcomes in Active Ankylosing Spondylitis: 28-Week Results of the Phase 3 Trial
John D. Reveille¹, Atul A. Deodhar², Eric K.H. Chan³, Steven Peterson⁴, Nan Li⁴, Elizabeth C. Hsia⁵, Lilianne Kim⁴, Kim Hung Lo⁴, Diane D. Harrison⁴ and Chenglong Han⁶, ¹University of Texas McGovern Medical School, Houston, TX, ²Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ³Janssen Global Services, LLC, Raritan, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁶Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To evaluate patient-reported outcomes (PRO) of physical functioning, mental health functioning, health state, and health-related quality of life (HRQoL) in patients (pts) with active…
Abstract Number: 1828 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Study
Karel Pavelka¹, Alan J. Kivitz², Eva Dokoupilova³, Ricardo Blanco⁴, Marco Maradiaga⁵, Hasan Tahir⁶, Alan Slade⁷, Yi Wang⁷, Susanne Rohrer⁸ and Brian Porter⁷, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Altoona Center for Clinical Research, Duncansville, PA, ³MEDICAL PLUS s.r.o., Uherske Hradiste, Czech Republic, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, Mexico, ⁶Barts Health NHS Trust, London, United Kingdom, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) improved the signs and symptoms of AS in 2 Phase 3 studies (MEASURE 1 and 2).1,2 Here, we present interim results through…
Abstract Number: 2804 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Patients with Ankylosing Spondylitis: A Nationwide Population Study
Yao-Fan Fang, Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Taoyuan, Taiwan
Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide population study.Background/Purpose: Autoimmune inflammatory diseases influence on pregnancy outcomes. But rare studies have focus on the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].